Literature DB >> 2760232

Abnormal platelet aggregation in patients with Raynaud's phenomenon.

M L Biondi1, B Marasini.   

Abstract

Platelet aggregation in vitro to several aggregating agents (serotonin (5-HT), adenosine diphosphate, adrenaline and collagen) was studied in 16 patients with primary and secondary Raynaud's phenomenon and compared with that in 13 normal volunteers. Platelets from patients with Raynaud's phenomenon had significantly greater responses to all the 5-HT concentrations tested (p less than 0.001 for 10 microM; p less than 0.01 for 1 microM; p less than 0.05 for 0.1 microM; p less than 0.02 for 0.025 microM) and to low doses of adenosine diphosphate (p less than 0.01 for 1 microM; p less than 0.02 for 0.5 microM) but normal responses to collagen, adrenaline, and high doses of adenosine diphosphate. Patients with secondary Raynaud's phenomenon were significantly more hypersensitive to 0.5 microM adenosine diphosphate than patients with primary Raynaud's phenomenon. In patients with secondary Raynaud's phenomenon there was a significant correlation between the extent of 5-HT aggregation and the duration of the disease. The finding that platelets from patients with Raynaud's phenomenon have enhanced responses to 5-HT and adenosine diphosphate, but normal responses to adrenaline and collagen, is consistent with a role for 5-HT in this disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2760232      PMCID: PMC1142020          DOI: 10.1136/jcp.42.7.716

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.

Authors:  I A Reilly; L Roy; G A Fitzgerald
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-19

2.  Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.

Authors:  J R Seibold; C A Terregino
Journal:  J Rheumatol       Date:  1986-04       Impact factor: 4.666

3.  Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.

Authors:  B Marasini; M L Biondi; E Bianchi; P Dell'Orto; A Agostoni
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.

Authors:  O K Roald; E Seem
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-08

5.  Plasma exchange and platelet function in Raynaud's phenomenon.

Authors:  J Zahavi; W A Hamilton; M J O'Reilly; J Leyton; L T Cotton; V V Kakkar
Journal:  Thromb Res       Date:  1980 Jul 1-15       Impact factor: 3.944

6.  Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon.

Authors:  C G Kallenberg; E Vellenga; A A Wouda; T H The
Journal:  J Rheumatol       Date:  1982 Nov-Dec       Impact factor: 4.666

7.  T gamma subset specificity of lymphocyte reactive factors in juvenile rheumatoid arthritis and systemic lupus erythematosus sera.

Authors:  R C Williams; C J Froelich; K Kilpatrick; W E Crowe; J E Levinson
Journal:  Arthritis Rheum       Date:  1981-04

8.  Assessment of platelet function in patients with Raynaud's syndrome.

Authors:  R A Hutton; D P Mikhailidis; R M Bernstein; J Y Jeremy; G R Hughes; P Dandona
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

9.  Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon.

Authors:  M L Biondi; B Marasini; E Bianchi; A Agostoni
Journal:  Int J Cardiol       Date:  1988-06       Impact factor: 4.164

10.  Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.

Authors:  J Lukác; J Rovenský; H Tauchmannová; D Zitnan
Journal:  Drugs Exp Clin Res       Date:  1985
  10 in total
  3 in total

1.  Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.

Authors:  B Marasini; M L Biondi; R Mollica
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Platelet aggregation in Raynaud's phenomenon.

Authors:  G Slutsker
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

3.  Subclavian vein thrombosis in a patient with Raynaud's disease.

Authors:  P Laguna; M A Sánchez; M Moya
Journal:  Postgrad Med J       Date:  1994-04       Impact factor: 2.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.